GRI
GRI Bio, Inc. (GRI) SWOT Analysis Analysis (2026)
No material changes this month.
Strengths
Liquidity is exceptionally strong with a current and quick ratio above 10x, giving GRI more near-term balance-sheet flexibility than most peers.
Debt-to-equity is extremely low at 0.004x, indicating materially lighter leverage than peers and reducing refinancing pressure across the cycle.
Cash conversion cycle is reported at zero, suggesting working-capital discipline that supports operational resilience relative to peers with longer cash cycles.
Weaknesses
ROIC is deeply negative at -93.8%, showing capital is not earning its cost and placing GRI well below profitable peers on structural efficiency.
Net debt to EBITDA of 1.13x is manageable, but it still leaves GRI more leveraged than net-cash peers with stronger earnings coverage.
The absence of reported operating and gross margins limits visibility, but the available profitability signal remains materially weaker than peer norms.
Opportunities
If management converts its strong liquidity into higher-return assets, GRI could narrow the profitability gap versus peers with better capital deployment.
Low leverage creates capacity to fund restructuring or growth initiatives more flexibly than peers already constrained by heavier debt loads.
A zero cash conversion cycle provides a base for sustaining working-capital efficiency, which can improve relative margin resilience if demand stabilizes.
Threats
Persistently negative ROIC threatens long-term competitive positioning because peers with positive returns can compound capital while GRI destroys value.
If earnings remain weak, even moderate net debt can become more burdensome than peers with stronger cash generation and lower leverage.
Limited margin disclosure increases uncertainty, and peers with clearer profitability trends may attract capital and customer confidence more easily.
Overall Score
GRI’s balance-sheet liquidity is strong, but structurally weak capital returns and limited profitability evidence leave its peer positioning below average overall.
Sources
- Company filings (10-K, 10-Q, investor presentations)
- Financial and market data providers
- Public news and industry information
🔒 Go Beyond This Framework
This is one of 10 institutional-grade frameworks Invetso runs on GRI Bio, Inc.. Unlock the complete analysis — SWOT, Economic Moat, Porter’s Five Forces, Management, PESTLE and the Invetso Quality Score.
